Lyell Immunopharma, Inc.
LYEL
$10.76
-$0.21-1.91%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 276.79M | 301.18M | 370.53M | 440.55M | 491.12M |
| Total Receivables | -- | -- | -- | -- | -- |
| Inventory | -- | -- | -- | -- | -- |
| Prepaid Expenses | 5.42M | 8.00M | 9.07M | 9.50M | 8.71M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 282.21M | 309.18M | 379.59M | 450.05M | 499.82M |
|
|
|||||
| Total Current Assets | 282.21M | 309.18M | 379.59M | 450.05M | 499.82M |
| Net Property, Plant & Equipment | 60.07M | 67.77M | 72.94M | 124.71M | 130.79M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | -- | -- | -- | -- | -- |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 4.11M | 4.91M | 6.31M | 5.35M | 4.53M |
| Total Assets | 385.45M | 429.80M | 490.86M | 619.22M | 654.14M |
|
|
|||||
| Total Accounts Payable | 3.38M | 3.73M | 5.37M | 3.60M | 4.20M |
| Total Accrued Expenses | 19.49M | 22.93M | 29.37M | 21.88M | 18.77M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 8.51M | 8.24M | 7.97M | 7.13M | 6.90M |
| Total Finance Division Other Current Liabilities | 5.53M | 6.39M | 11.08M | 907.00K | 1.01M |
| Total Other Current Liabilities | 5.53M | 6.39M | 11.08M | 907.00K | 1.01M |
| Total Current Liabilities | 36.90M | 41.29M | 53.79M | 33.51M | 30.88M |
|
|
|||||
| Total Current Liabilities | 36.90M | 41.29M | 53.79M | 33.51M | 30.88M |
| Long-Term Debt | -- | -- | -- | -- | -- |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 46.60M | 48.85M | 50.99M | 51.44M | 53.32M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 3.03M | 3.14M | 3.25M | 3.57M | 3.44M |
| Total Liabilities | 86.53M | 93.28M | 108.04M | 88.52M | 87.64M |
|
|
|||||
| Common Stock & APIC | 1.74B | 1.73B | 1.73B | 1.68B | 1.68B |
| Retained Earnings | -1.44B | -1.40B | -1.35B | -1.15B | -1.11B |
| Treasury Stock & Other | 57.00K | 158.00K | 291.00K | 760.00K | -397.00K |
| Total Common Equity | 298.92M | 336.52M | 382.82M | 530.70M | 566.50M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 298.92M | 336.52M | 382.82M | 530.70M | 566.50M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 298.92M | 336.52M | 382.82M | 530.70M | 566.50M |
|
|
|||||